Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. - Wikidata - wikimedia - TriplyDB

Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease.

Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease.

http://www.wikidata.org/entity/Q44901723

about

The relevance of beta-amyloid on markers of Alzheimer's disease in clinically normal individuals and factors that influence these associations The Alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriers Harmonized diagnostic criteria for Alzheimer's disease: recommendations Association of Longitudinal Cognitive Decline With Amyloid Burden in Middle-aged and Older Adults: Evidence for a Dose-Response Relationship.A clinical trial to validate event-related potential markers of Alzheimer's disease in outpatient settings.Recent imaging advances in neurology.Associations between cerebral amyloid and changes in cognitive function and falls risk in subcortical ischemic vascular cognitive impairment.Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease.Imaging Brain Metabolism and Pathology in Alzheimer's Disease with Positron Emission Tomography.Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease.Relationships between default-mode network connectivity, medial temporal lobe structure, and age-related memory deficits The evolution of preclinical Alzheimer's disease: implications for prevention trials.Effect of BDNF Val66Met on memory decline and hippocampal atrophy in prodromal Alzheimer's disease: a preliminary study.Systematic review of the relationship between amyloid-β levels and measures of transgenic mouse cognitive deficit in Alzheimer's disease.Brain structure and function as mediators of the effects of amyloid on memory.Sensitivity of negative subsequent memory and task-negative effects to age and associative memory performance Imaging brain effects of APOE4 in cognitively normal individuals across the lifespan.Amyloid-Related Memory Decline in Preclinical Alzheimer's Disease Is Dependent on APOE ε4 and Is Detectable over 18-Months.Age and amyloid effects on human central nervous system amyloid-beta kinetics.Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community Evaluating Alzheimer's Disease Progression by Modeling Crosstalk Network Disruption Independent and Interactive Influences of the APOE Genotype and Beta-Amyloid Burden on Cognitive Function in Mild Cognitive Impairment Brain Events Underlying Episodic Memory Changes in Aging: A Longitudinal Investigation of Structural and Functional Connectivity.APOE and BDNF polymorphisms moderate amyloid β-related cognitive decline in preclinical Alzheimer's disease.Back to the future: Alzheimer's disease heterogeneity revisited.Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: Introducing the Z-scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score.Beta-amyloid and cognitive decline in late middle age: Findings from the Wisconsin Registry for Alzheimer's Prevention study.Is amyloid-β harmful to the brain? Insights from human imaging studies Cognitive impairment and decline in cognitively normal older adults with high amyloid-β: A meta-analysis.Amyloid-beta and depression in healthy older adults: a systematic review.Systematic review of strengths and limitations of randomized controlled trials for non-pharmacological interventions in mild cognitive impairment: focus on Alzheimer's disease.Early functional network alterations in asymptomatic elders at risk for Alzheimer's disease Temporal Order of Alzheimer's Disease-Related Cognitive Marker Changes in BLSA and WRAP Longitudinal Studies.Polygenic risk of Alzheimer disease is associated with early- and late-life processes.Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid β.BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease.Brain Amyloid Deposition Is Associated With Lower Instrumental Activities of Daily Living Abilities in Older Adults. Results From the MAPT Study.[Formula: see text]Practice effects and longitudinal cognitive change in clinically normal older adults differ by Alzheimer imaging biomarker status.

P2860

Q26830467-CD2D7EE0-B7F8-4616-8DC8-2A51CEFC9801 Q26849380-A21ACF09-CD3E-47B8-B2C7-E0447490DBFF Q27009157-87013383-DD64-444D-9E6F-89B497D923CA Q30101023-52E2BA55-42E6-4FB2-B784-262F0607CC8D Q30382854-AE8B864E-A1B3-4435-8700-82CAAAAA9D39 Q30916063-BCEA4A80-A366-4CA4-BEA7-8E78EBEBFCD7 Q33850834-F8A3D53D-51CD-4F0E-8E1B-928B495AFBA6 Q34286393-DDE8D229-22E4-4A8E-A334-BAE489DD0528 Q34364368-BD646BCE-C306-4449-A57C-F21090BD1A2B Q34378321-04F4EEF7-B764-4E63-B51D-A24D3605B4B3 Q34477459-409A5BF1-0A1B-481E-9D7B-DF3C69CC20BE Q34718075-9F4B515E-6289-4406-8F72-21C99E870FC1 Q34849048-4E79FF95-E4C3-4519-8B22-39EC0514D71F Q35086470-BCE71F80-36E1-4D74-954F-E3C140A763D2 Q35137134-748D5216-1880-465D-B2F5-BDF2E87F4AD2 Q35211063-1BEC0156-F131-41DC-B4AA-1CFE189E7AA2 Q35225927-CBEE24D1-C2BF-4EE6-AE90-4E7CE77FCD24 Q35229601-1E1D6B10-1EBD-4227-AE93-B4E61ED71C31 Q35796631-DF8F2ED2-FD8A-4BE1-98FB-763B079E7914 Q35987665-CE9AF6AC-6FD5-4660-B7B4-D4C7797A4C71 Q36005633-E3AC5C15-EF17-4CD9-B713-D353DCFB931E Q36456068-15A54B8C-F70B-4759-855D-DB6A50C2A4B4 Q36477601-1D62F9A2-8022-47B3-9BC6-ADED8A6CB97A Q36510006-401BC18D-3A45-4BF5-8503-AB7FB5704EBB Q36533839-5261D485-BC8C-4986-A81F-972F850811F4 Q36594552-A96BCEA8-0204-4A69-A316-100C355DE19F Q36785505-9065357E-D198-4686-B375-BDCDE65FD422 Q36934154-31EB4ED6-C5CC-4799-9E52-36AE69992CD3 Q37100074-1D219EF1-0E6E-463D-8488-76E9E3967D55 Q37188315-751A6AF7-5E70-436C-864A-AB4ED8B65F92 Q37650253-17968718-7DAD-45B6-A379-CF07C6FC5919 Q38270148-D9ABCE3A-40EF-41D0-A9F7-974307202CDA Q38344080-0865C99E-A321-45C0-BB71-4FBF4E5A162C Q38659127-F7332F5E-5D53-4F6C-877D-21DE2C4431C6 Q38668225-A24B42E1-7E21-4961-93D0-6A8A77D9DE4C Q38844567-5EEE5B7C-F4B7-4B73-BA9E-C514CD0B8F25 Q38933111-838CDD19-5684-4DA6-9341-42D7C3592BE5 Q39493228-6BF8421E-74BB-4924-9EE7-E6E1A5A97702 Q40485355-DC42BE4F-0088-475E-8B03-2FC3DBAB625D Q40547789-664E8B64-DC46-4FD3-B0AA-80A07A738869

P2860

Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease.

http://www.wikidata.org/entity/Q44901723

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Effect of amyloid on memory an ...... clinical Alzheimer's disease.

@en

Effect of amyloid on memory an ...... clinical Alzheimer's disease.

@nl

type

label

Effect of amyloid on memory an ...... clinical Alzheimer's disease.

@en

Effect of amyloid on memory an ...... clinical Alzheimer's disease.

@nl

prefLabel

Effect of amyloid on memory an ...... clinical Alzheimer's disease.

@en

Effect of amyloid on memory an ...... clinical Alzheimer's disease.

@nl

P1433

Q44901723-A339BE27-F2FC-442E-91A7-F053FB5BCE86

P1476

Q44901723-E070DA95-CDB4-422E-8B34-9B65F23CC24F

P2093

Q44901723-112C1351-7D37-46B9-90A5-28028AD3B5EB

Q44901723-17531A51-90EF-49C1-860E-3BC12F1B23F4

Q44901723-217141C5-D2ED-4E6C-9D6F-23F694A4D99D

Q44901723-6218BE11-698E-45CB-8C1F-0C20B17BEBB2

Q44901723-637D728E-ECE0-4CEE-8548-AFD3AD505A51

Q44901723-91A1A158-73CE-4A6E-B491-059EBC6665D9

Q44901723-B8F014AF-97FC-4B1C-8E32-66993BC5BD3B

Q44901723-D18F224F-6C74-470C-A890-B8E9FDE31953

P2860

Q44901723-046AAC74-056F-4AD9-87E0-E7503F1D286F

Q44901723-07029053-7E4F-43E3-83B7-D4E776485498

Q44901723-17687E03-8ACA-409C-B43D-B33E53FF8CBB

Q44901723-299145F8-9BAF-468A-808D-272493317F29

Q44901723-2E85A1A3-FDC0-4B5C-B625-0AF303FAE652

Q44901723-2FD6A52A-3944-4FFD-91DE-C28CAD807254

Q44901723-38565700-4F8C-4EF5-8A2E-ADC4FA30999E

Q44901723-393F9D04-4AE7-44F3-92A9-B8AD6CB25FF3

Q44901723-40111C8F-B612-4B93-A34E-AFF7E5540171

Q44901723-4327AE07-7D70-46AC-97D4-68D5AB80E37D

P304

Q44901723-9316C15D-1627-4459-BE5D-87E2F79D3200

P31

Q44901723-EEC68689-2E00-46FF-97C6-3BC1826EBAA7

P356

Q44901723-5079C1D6-3A98-451A-8DE6-C699F74A7040

P407

Q44901723-490BA372-7694-4FAC-A48F-1FAE314A6AEA

P433

Q44901723-569273D2-2FAE-4066-B0A7-1994EFEE4C62

P478

Q44901723-32DC6324-9C8F-4055-A979-1BCBDF27BDDD

P50

Q44901723-193ADE75-1FD9-4B06-A94A-DBE08BE3FB4E

Q44901723-686F080D-9D98-4B1D-A8BD-1FF12148CDD2

Q44901723-96C31ABA-4391-4849-8A9B-DCAEC032CA57

Q44901723-97966E05-A174-45A1-B298-23408023EC8D

Q44901723-C44EECAA-11F6-45B1-8CB6-B63B0AF05B72

P577

Q44901723-3667F4B5-1FCC-4379-9550-589938F3D0AB

P5875

Q44901723-3EBC13C9-E47E-48EC-8028-D01E0CA11177

P698

Q44901723-716111C0-B4BD-4E3C-A224-E7A768A0A68C

P921

Q44901723-CEC7E92F-321E-4B14-A715-E3AC66F9E3F8

P356

P1433

P1476

Effect of amyloid on memory an ...... clinical Alzheimer's disease.

@en

P2093

AIBL Research Group

http://www.w3.org/2001/XMLSchema#string

Christopher C Rowe

http://www.w3.org/2001/XMLSchema#string

David Ames

http://www.w3.org/2001/XMLSchema#string

Karra Harrington

http://www.w3.org/2001/XMLSchema#string

Nicola T Lautenschlager

http://www.w3.org/2001/XMLSchema#string

Robert H Pietrzak

http://www.w3.org/2001/XMLSchema#string

Victor L Villemagne

http://www.w3.org/2001/XMLSchema#string

Yen Ying Lim

http://www.w3.org/2001/XMLSchema#string

P2860

Use of Florbetapir-PET for Imaging β-Amyloid Pathology

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18)

11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment

“Mini-mental state”

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

Neuropathological stageing of Alzheimer-related changes

Mild cognitive impairment: clinical characterization and outcome

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

P304

221-231

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/BRAIN/AWT286

http://www.w3.org/2001/XMLSchema#string

P407

P433

Pt 1

http://www.w3.org/2001/XMLSchema#string

P478

137

http://www.w3.org/2001/XMLSchema#string

P50

Colin L. Masters

Cassandra Szoeke

Kathryn A Ellis

P577

2013-10-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261437519

http://www.w3.org/2001/XMLSchema#string

P698

24176981

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease